In:
Case Reports in Oncology, S. Karger AG, Vol. 15, No. 1 ( 2022-3-31), p. 376-381
Abstract:
The 〈 i 〉 c-ros oncogene 1 (ROS1) 〈 /i 〉 fusion gene is a rare genomic alteration detected in nearly 1–2% of lung adenocarcinomas. The major partner genes of 〈 i 〉 ROS1 〈 /i 〉 include 〈 i 〉 CD74 〈 /i 〉 , 〈 i 〉 SDC4 〈 /i 〉 , and 〈 i 〉 EZR 〈 /i 〉 . Here, we report a case of 〈 i 〉 MYH9-ROS1 〈 /i 〉 fusion gene-positive lung adenocarcinoma, a rare 〈 i 〉 ROS1 〈 /i 〉 fusion gene. The patient was a woman in her 40s who was diagnosed with advanced primary lung adenocarcinoma after a thorough examination. Initial genetic testing conducted using mediastinal lymph node biopsy specimens collected by endobronchial ultrasound-guided transbronchial needle aspiration revealed no driver gene mutations, including the 〈 i 〉 ROS1 〈 /i 〉 fusion gene. The patient was treated with four courses of immunochemotherapy. As the disease worsened, another genetic test was conducted using FoundationOne 〈 sup 〉 ® 〈 /sup 〉 CDx, and the 〈 i 〉 MYH9-ROS1 〈 /i 〉 fusion gene was detected. Multiple lung metastases disappeared after the administration of entrectinib; the response persisted up to a year. Adverse events of rash, dysgeusia, and peripheral edema were observed, and the patient required temporary drug interruption; however, we were able to continue entrectinib following a short-term drug interruption. This is the first report on the effectiveness of entrectinib against lung adenocarcinoma with the rare 〈 i 〉 MYH9-ROS1 〈 /i 〉 fusion gene.
Type of Medium:
Online Resource
ISSN:
1662-6575
Language:
English
Publisher:
S. Karger AG
Publication Date:
2022
detail.hit.zdb_id:
2458961-5
Permalink